Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating retinal diseases

A retinal, composition-based technology for stem cell biology and regenerative medicine that addresses pluripotent cell contamination, low graft yield and efficiency

Active Publication Date: 2014-03-26
RGT UNIV OF CALIFORNIA
View PDF25 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the yield and efficiency of graft engraftment are low and contamination with residual tumor-forming pluripotent cells is also a problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating retinal diseases
  • Compositions and methods for treating retinal diseases
  • Compositions and methods for treating retinal diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0237] Example 1: Isolation and culture of retinal progenitor cells

[0238] Whole fetal eyes of fetuses of approximately 16 to 19 weeks of gestational age (GA) were obtained from donors and placed in 15 ml tubes containing RPMI-1640 medium containing L-glutamine (BioWhittaker). Eyes were transported on ice for a period of time ranging from 4.5 hours to about 21.5 hours. At the same time, a blood sample from the donor is drawn and sent for testing for exposure to exogenous agents. Upon arrival, each eyeball is inspected to ensure that the cornea is clear and of normal shape, and the eyeball is then placed in a laminar flow clean bench under sterile conditions. Whole fetal eyes were rinsed three times with 40 ml of cold phosphate buffered saline (PBS) containing antibiotics in separate 50 ml tubes. The optic nerve and remaining mesenchymal tissue are then removed by dissection. This method was developed to avoid contamination of possible retinal isolates with unwanted cells ...

Embodiment 2

[0254] Example 2: Characterization of RPC

[0255] Immunocytochemistry

[0256] Cells were dissociated and grown on 4- or 8-well chamber slides for 1-3 days, then fixed in 4% paraformaldehyde for 15 minutes and washed 3 times in PBS. Slides were blocked for 1 hour in a solution containing 5% donkey serum and / or 0.3% Triton X-100, then washed again with PBS. It was then incubated overnight at 4°C with a panel of antibodies to detect antigens expressed by the progenitor cells. This includes anti-nestin antibody (Chemicon1:200), anti-vimentin antibody (Sigma1:200), anti-Sox2 antibody (Santa Cruz1:400), anti-SSEA-1 antibody (BD1:200), anti-GD2 antibody (Chemicon1:100 ), anti-Ki-67 antibody (BD1:200), anti-β3-tubulin antibody (Chemicon1:400), anti-GFAP antibody (Chemicon1:400), and anti-GDNF antibody (Santa Cruz1:200). Then incubated with anti-mouse Alexa546 (Invitrogen 1:400), anti-goat Alexa488 (Invitrogen 1:400), or anti-rabbit FITC (Chemicon 1:800) secondary antibody. Fluor...

Embodiment 3

[0312] Example 3: In vivo effectiveness of RPCs

[0313] RPCs for transplantation were first prepared by harvesting RPCs with TrypLE Express and centrifuging at 1000 rpm for 5 minutes to collect the RPCs. Cells were washed once in HBSS and then resuspended in cold HBSS to determine cell viability and cell number. For human transplants, use 0.5 × 10 in 100 μl HBSS 6 cells. For transplantation into rats, different doses ranging from 4000 to 75,000 cells in 2 μl of HBSS were used.

[0314] Human RPCs were transplanted as a suspension into the vitreous or subretinal space of dystrophic hooded RCS rats. Rats were given cyclosporin A and steroids to avoid xenograft rejection. Control eyes received sham injections (subretinal, intravitreal) consisting of vehicle only. Transplanted animals were functionally tested in an unrestrained wakefulness state using a commercial instrument designed to quantify optokinetic response (OR). Test the brightness threshold of a subgroup of anima...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.

Description

technical field [0001] The subject matter described herein relates generally to the fields of stem cell biology and regenerative medicine. In particular, the subject matter disclosed herein provides compositions and methods for treating, alleviating or preventing retinal diseases or disorders by administering retinal progenitor cells; improving photopic (daylight) vision, improving or correcting visual acuity, improving macular function, improve vision, or improve dark (night) vision. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolating them. In alternative embodiments, the present invention provides compositions and methods for treating, alleviating or preventing retinal diseases or conditions, e.g., Usher's disease, retinitis pigmentosa (RP), degenerative retinal age-related macular degeneration (AMD), wet or dry AMD, geographic atrophy, retinal photoreceptor disease, diabetic retinopathy, cystoid m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P27/02A61P27/00A61K35/30
CPCC12N5/0623A61K9/0048A61K35/30A61P27/00A61P27/02A61P27/06A61P27/10A61P9/10A61K48/00A61K9/0019C12N5/0621C12N2509/00C12N2500/02C12N2500/38C12N2500/90C12N2533/52
Inventor 亨利·克拉森杨静
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com